Health

Duchenne Drug Approvals and Leadership Changes

Updated 2026-07-30 19:10 UTC 1 source Neutral

Capricor faces scrutiny over FDA's inconsistent approaches to Duchenne drugs. New executives in the company may also impact its operations.

Coverage timeline — 1 article

STAT News

Capricor’s data clash and a fugitive in the C-suite

Is the FDA taking inconsistent approaches to Duchenne drugs? And how will a new batch of drug executives shake up their companies? Find out on the latest episode of "The…

2026-07-30 19:03 UTC